CrystalGenomics Inc
KOSDAQ:083790
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
Microsoft Corp
SGO:MSFT
|
US |
CrystalGenomics Inc
Common Stock
CrystalGenomics Inc
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
CrystalGenomics Inc
KOSDAQ:083790
|
Common Stock
₩38.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
11%
|
CAGR 10-Years
12%
|
|
|
Celltrion Inc
KRX:068270
|
Common Stock
₩239.4B
|
CAGR 3-Years
19%
|
CAGR 5-Years
12%
|
CAGR 10-Years
8%
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Common Stock
₩9.2B
|
CAGR 3-Years
18%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Common Stock
₩26.8B
|
CAGR 3-Years
1%
|
CAGR 5-Years
14%
|
CAGR 10-Years
25%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Common Stock
₩27.6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
D
|
DND PharmaTech Inc
KOSDAQ:347850
|
Common Stock
₩5.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
CrystalGenomics Inc
Glance View
CrystalGenomics, Inc. engages in the discovery and development of novel therapeutics. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2006-01-06. The firm operates its business through four segments. The Drug Substance Manufacturing segment manufactures and sells drug substances such as anti-inflammatory analgesics, antispasmodics, and asthma treatments. The Finished Drug Manufacturing segment produces and supplies finished drugs such as cephalosporin antibiotics. The Pharmaceutical Research and Development segment is engaged in the provision of clinical trial analysis and technical services, and sales of new drugs. The company also engages in real estate rental business. The Other segment is engaged in the manufacture and sale of hot pats and other household goods.
See Also
What is CrystalGenomics Inc's Common Stock?
Common Stock
38.4B
KRW
Based on the financial report for Dec 31, 2025, CrystalGenomics Inc's Common Stock amounts to 38.4B KRW.
What is CrystalGenomics Inc's Common Stock growth rate?
Common Stock CAGR 10Y
12%
Over the last year, the Common Stock growth was 0%. The average annual Common Stock growth rates for CrystalGenomics Inc have been 3% over the past three years , 11% over the past five years , and 12% over the past ten years .
